top of page

Since winning a pitch competition a year ago, Synthis Therapeutics has been working out of JLABS' Manhattan location on a TGF-β antibody drug conjugate

Oct 21, 2024
1 min read

Founder & CEO Dori Thomas-Karyat describes why she believes a local delivery approach to the tumor is the solution to the shortcomings that other, mostly systemic, TGF-β programs have faced.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page